Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma
Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence. Here, we aim to understand the mechanisms of action of cisplatin and emergence of resistance to cisplatin using mass spectrometry-ba...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/23723556.2024.2328873 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850247990569074688 |
|---|---|
| author | Ankit P. Jain Vivek Ghose Srijon Munshi Firdous A. Bhat Gourav Dey Vishalakshi Nanjappa |
| author_facet | Ankit P. Jain Vivek Ghose Srijon Munshi Firdous A. Bhat Gourav Dey Vishalakshi Nanjappa |
| author_sort | Ankit P. Jain |
| collection | DOAJ |
| description | Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence. Here, we aim to understand the mechanisms of action of cisplatin and emergence of resistance to cisplatin using mass spectrometry-based proteomic approach. A panel of head and neck squamous cell carcinoma (HNSCC) cell lines were treated with cisplatin at respective IC50 for 24 h and label-free mass spectrometry analysis was carried out. Proteomic analysis of A253, FaDu, Det562 and CAL27 cell lines upon cisplatin treatment resulted in the identification of 5,060, 4,816, 4,537 and 4,142 proteins, respectively. Bioinformatics analysis of differentially regulated proteins revealed proteins implicated in DNA damage bypass pathway, translation and mRNA splicing to be enriched. Further, proteins associated with cisplatin resistance exhibited alterations following short-term cisplatin exposure. Among these, class III tubullin protein (TUBB3) was found to be upregulated in cisplatin-treated cells compared to untreated cells. Western blot analysis confirmed the elevated expression of TUBB3 in cells treated with cisplatin for 24 h, and also in cisplatin resistant HNSCC cell lines. This study delineates the early signaling events that enable HNSCC cells to counteract the cytotoxic effects of cisplatin and facilitate the development of resistance. |
| format | Article |
| id | doaj-art-a6f31874312c4bd3a783f4a4ab77fa78 |
| institution | OA Journals |
| issn | 2372-3556 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj-art-a6f31874312c4bd3a783f4a4ab77fa782025-08-20T01:58:48ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562024-12-0111110.1080/23723556.2024.2328873Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinomaAnkit P. Jain0Vivek Ghose1Srijon Munshi2Firdous A. Bhat3Gourav Dey4Vishalakshi Nanjappa5Institute of Bioinformatics, International Technology Park, Bangalore, IndiaInstitute of Bioinformatics, International Technology Park, Bangalore, IndiaInstitute of Bioinformatics, International Technology Park, Bangalore, IndiaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USAInstitute of Bioinformatics, International Technology Park, Bangalore, IndiaInstitute of Bioinformatics, International Technology Park, Bangalore, IndiaCisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence. Here, we aim to understand the mechanisms of action of cisplatin and emergence of resistance to cisplatin using mass spectrometry-based proteomic approach. A panel of head and neck squamous cell carcinoma (HNSCC) cell lines were treated with cisplatin at respective IC50 for 24 h and label-free mass spectrometry analysis was carried out. Proteomic analysis of A253, FaDu, Det562 and CAL27 cell lines upon cisplatin treatment resulted in the identification of 5,060, 4,816, 4,537 and 4,142 proteins, respectively. Bioinformatics analysis of differentially regulated proteins revealed proteins implicated in DNA damage bypass pathway, translation and mRNA splicing to be enriched. Further, proteins associated with cisplatin resistance exhibited alterations following short-term cisplatin exposure. Among these, class III tubullin protein (TUBB3) was found to be upregulated in cisplatin-treated cells compared to untreated cells. Western blot analysis confirmed the elevated expression of TUBB3 in cells treated with cisplatin for 24 h, and also in cisplatin resistant HNSCC cell lines. This study delineates the early signaling events that enable HNSCC cells to counteract the cytotoxic effects of cisplatin and facilitate the development of resistance.https://www.tandfonline.com/doi/10.1080/23723556.2024.2328873Mass spectrometrydrug resistancecisplatinhead and neck cancerproteomics |
| spellingShingle | Ankit P. Jain Vivek Ghose Srijon Munshi Firdous A. Bhat Gourav Dey Vishalakshi Nanjappa Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma Molecular & Cellular Oncology Mass spectrometry drug resistance cisplatin head and neck cancer proteomics |
| title | Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| title_full | Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| title_fullStr | Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| title_full_unstemmed | Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| title_short | Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| title_sort | mass spectrometry based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma |
| topic | Mass spectrometry drug resistance cisplatin head and neck cancer proteomics |
| url | https://www.tandfonline.com/doi/10.1080/23723556.2024.2328873 |
| work_keys_str_mv | AT ankitpjain massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma AT vivekghose massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma AT srijonmunshi massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma AT firdousabhat massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma AT gouravdey massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma AT vishalakshinanjappa massspectrometrybasedproteomicanalysistocharacterizecisplatininducedearlysignalingeventsinheadandnecksquamouscellcarcinoma |